Information Provided By: 
Fly News Breaks for November 26, 2019
AGIO
Nov 26, 2019 | 07:02 EDT
Cantor Fitzgerald analyst Alethia Young initiated coverage of Agios Pharmaceuticals with an Overweight rating and $64 price target. Although shares were under pressure in 2019, there are catalysts on the horizon and overhangs lifted like financing "that should clear the way for 2020 outperformance," Young tells investors in a research note. She believes Agios has a "robust R&D engine" focused on cellular metabolism and precision medicine for cancer and rare genetic diseases.
News For AGIO From the Last 2 Days
There are no results for your query AGIO
